Fred Aslan - 18 Jul 2024 Form 3 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
President and CEO, Director
Signature
/s/ Jennifer Bush, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
18 Jul 2024
Net transactions value
$0
Form type
3
Filing time
18 Jul 2024, 20:00:09 UTC
Next filing
07 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 257,319 $5.01 Direct F1
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 51,463 $5.01 Direct F2
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 100,577 $5.01 Direct F3
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 26,450 $5.18 Direct F4
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 113,999 $13.47 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares vested on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F2 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F3 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
F5 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.